전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved4 programs
AntibodyCurated CoreFDANovo NordiskApproved

semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535)

Type 2 diabetes, chronic weight management, CV risk reduction (T2D) · GLP-1 receptor

#GLP-1receptor#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 410Status Approved
AntibodyCurated CoreFDAEli LillyApproved

tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176)

Type 2 diabetes, chronic weight management · GLP-1 / GIP receptor

#GLP-1GIPreceptor#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 269Status Approved
AntibodyCurated CoreFDAargenxApproved

efgartigimod (Vyvgart, ARGX-113, Vyvgart Hytrulo, efgartigimod alfa-fcab)

Generalized myasthenia gravis (AChR antibody positive), chronic inflammatory demyelinating polyneuropathy · FcRn (neonatal Fc receptor)

#FcRnneonatalFcreceptor#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 48Status Approved
AntibodyCurated CoreFDAAstraZenecaApproved

tezepelumab (Tezspire, AMG 157, MEDI9929, tezepelumab-ekko)

Severe asthma add-on maintenance, chronic rhinosinusitis with nasal polyps · TSLP (thymic stromal lymphopoietin)

#TSLPthymicstromallymphopoietin#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 47Status Approved